Literature DB >> 35253931

Single-agent daratumumab for refractory POEMS syndrome.

Han Wei Tiew1, Venkata Sreekanth Sampath1,2,3,4, Christian Aledia Gallardo1, Dheepa Christopher1,2,3,4, Stephrene Seok Wei Chan1,2,3,4, Shiun Woei Wong3,4,5, Allison Ching Yee Tso1,2,3,4, Lian King Lee1,2,3,4, Bingwen Eugene Fan1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35253931     DOI： 10.1002/ajh.26517

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  1 in total

1.  First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS).

Authors:  Omur Gokmen Sevindik; Yasa Gul Mutlu; Berrin Balik Aydin; Istemi Serin
Journal:  Hemasphere       Date:  2022-06-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.